As a result, KRAS mutations generally affect consistent percentages of Caucasian (21–33%, 21.3% in our series) and to a lesser extend Asian (2–15%) patients with lung adenocarcinoma [7, 10], representing therefore an attractive target for future treatments. The gene discussed is KRAS; the disease is lung adenocarcinoma.